Home Drug Discovery Antibodies RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision

3d illustration of a part of RNA chain from which the deoxyribonucleic acid or DNA is composed — Avidity Biosciences plans to enter the clinic with its first in a new class of oligonucleotide-based treatments this year. The company will study its lead pipeline candidate, AOC 1001, in a Phase I/II trial in adults with myotonic dystrophy type 1 (DM1), set to start in the second half of the year. [Christoph Burgstedt / iStock / Getty Images Plus]

Drug Discovery
Antibodies
Antibody Drug Conjugates
Cardiovascular Disease
Therapeutics
Cardiovascular Drugs
OMICs
DNA
GEN Edge
Immunology
Monoclonal Antibodies
Musculoskeletal Disorders
Oligonucleotides

RNA in Its DNA: Avidity Biosciences Combines mAb Selectivity, Oligonucleotide Precision

By Alex Philippidis

February 8, 2021

Avidity Biosciences plans to enter the clinic with its first in a new class of oligonucleotide-based treatments this year. The company will study its lead pipeline candidate, AOC 1001, in a Phase I/II trial in adults with myotonic dystrophy type 1 (DM1), set to start in the second half of the year. [Christoph Burgstedt / iStock / Getty Images Plus]

AOC 1001 is based on Avidity’s Antibody Oligonucleotide Conjugates (AOCs™) platform, designed to treat diseases of high unmet need by combining the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide therapies . . .